Fact based stock research
Dr. Hoenle (XTRA:HNL)


Dr. Hoenle stock research in summary

hoenle.de


Dr. Hoenle shares have a BUY rating. They show above average growth, are safely financed and are good value. We recommend buying and holding Dr. Hoenle shares.


Latest Obermatt Ranks


Country Germany
Industry Electr. Components & Equipment
Index CDAX
Size class X-Small

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Research History: Dr. Hoenle

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
93
96
70
54
STOCK GROWTH RANKS
50
45
76
88
STOCK SAFETY RANKS
100
87
69
60
COMBINED STOCK RANKS
50
90
78
100

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Dr. Hoenle in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Dr. Hoenle; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
34
28
33
60
PROFIT GROWTH
50
50
50
88
STOCK RETURNS
54
81
86
96
CONSOLIDATED RANK: GROWTH
50
45
76
88

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Dr. Hoenle.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
37
36
42
52
REFINANCING
90
82
82
38
LIQUIDITY
100
75
83
60
CONSOLIDATED RANK: SAFETY
100
87
69
60

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Dr. Hoenle and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Dr. Hoenle from June 8, 2018.